Inactive Instrument

LifeAssays AB (publ)

Equities

LIFE B

SE0011205459

Advanced Medical Equipment & Technology

LifeAssays AB (NGM:LIFE B) completed the acquisition of Magnasense Ltd. for €0.45 million.

November 23, 2015

LifeAssays AB (publ) (NGM:LIFE B) signed a non-binding letter of intent letter of intent to acquire Magnasense Ltd. in stock on August 17, 2015. LifeAssays will issue new shares as part of consideration. Lotta Pohjanpalo and Kim Ekqvist of Waselius & Wist acted as legal advisor to LifeAssays AB (publ) (NGM:LIFE B).

LifeAssays AB (publ) (NGM:LIFE B) completed the acquisition of Magnasense Ltd. for €0.45 million on November 5, 2015. LifeAssays AB will issue approximately 80.31 million B-shares to the owners of Magnasense Ltd.

Latest news about LifeAssays AB (publ)

AegirBio AB (OM:AEGIR) completed the acquisition of LifeAssays AB (NGM:LIFE B).	03/06/21	CI
Lifeassays AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	26/02/21	CI
AegirBio AB (OM:AEGIR) agreed to acquire LifeAssays AB (NGM:LIFE B) for approximately SEK 140 million.	24/01/21	CI
LifeAssays AB Auditor Raises 'Going Concern' Doubt	04/06/20	CI
Abreos Biosciences and Lifeassays® AB Form A Jointly Owned Company and Enter into Associated License Agreements	27/11/19	CI
An unknown buyer acquired unknown minority stake in LifeAssays AB (NGM:LIFE B) from Finansinspektionen.	25/06/19	CI
Unknown buyer acquired an unknown minority stake in LifeAssays AB (NGM:LIFE B) from Danske Bank A/S.	05/05/19	CI
LifeAssays AB announced that it has received SEK 6.459739 million in funding from Beijing St Grand Asset Management Co. Ltd.	08/03/17	CI
LifeAssays AB (NGM:LIFE B) completed the acquisition of Magnasense Ltd. for €0.45 million.	23/11/15	CI
LifeAssays AB (NGM:LIFE B) signed a non-binding letter of intent letter of intent to acquire Magnasense Ltd.	16/08/15	CI
LifeAssays AB Auditor Raises 'Going Concern' Doubt	21/04/15	CI

Chart LifeAssays AB (publ)

Duration

Period

More charts

Company Profile

LifeAssays publ AB is a Sweden-based diagnostic company. It is engaged in the provision of in-house diagnostic testing for community health centers and physicians, as well as for home use and veterinary applications. The Company develops and markets point-of-care testing (POCT) instruments and technology for the diagnosis of diabetes, renal dysfunction and cardiovascular diseases. The Company's business portfolio comprises such products, as LifeAssays Canine CRP Test Kit, which monitors inflammation in dogs for early disease intervention; LifeAssays CRP Test Kit, which is a reagent kit for high-sensitive C-Reactive Protein (hsCRP) and normal range C-Reactive Protein (CRP) in whole blood; LifeAssays Reader, which utilizes a disposable algorithm chip containing all reagent identification data, as well as, a self-executable algorithm; and LifeAssays Vet Reader, which offers veterinary practitioners all the functions provided with the LifeAssays Reader.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
SARTORIUS AG	-27.52%	16.33B
QUIDELORTHO CORPORATION	-40.04%	2.96B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+15.16%	1.82B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-6.86%	1.55B
BIOTAGE AB	+38.67%	1.41B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-15.36%	976M
CONTEC MEDICAL SYSTEMS CO.,LTD	-26.08%	846M
REVENIO GROUP OYJ	+3.53%	811M
VAREX IMAGING CORPORATION	-24.63%	631M

Medical Diagnostic & Testing Equipment